First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report.
Aged, 80 and over
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antineoplastic Agents, Immunological
/ therapeutic use
B7-H1 Antigen
/ metabolism
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
ErbB Receptors
/ genetics
Fatal Outcome
Female
Humans
Lung Neoplasms
/ drug therapy
Mutation
Epidermal growth factor receptor (EGFR) mutation
pembrolizumab
programmed death-ligand 1 (PD-L1)
squamous cell lung cancer
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
11
12
2019
revised:
26
03
2020
accepted:
27
03
2020
pubmed:
16
4
2020
medline:
16
3
2021
entrez:
16
4
2020
Statut:
ppublish
Résumé
A 90-year-old female was admitted to our hospital with a history of a dry cough. Chest computed tomography (CT) scan showed a tumor shadow, and CT-guided lung biopsy revealed squamous cell carcinoma harboring an EGFR mutation. In addition, programmed death-ligand 1 (PD-L1) was highly expressed with a tumor proportion score (TPS) of >75%. Pembrolizumab therapy in the first-line setting was not effective, and the patient died at six months from the first visit. Squamous cell lung cancers (SCLCs) with both EGFR mutation and high expression of PD-L1 are very rare.
Identifiants
pubmed: 32291904
doi: 10.1111/1759-7714.13436
pmc: PMC7262880
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
B7-H1 Antigen
0
CD274 protein, human
0
pembrolizumab
DPT0O3T46P
EGFR protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1716-1719Informations de copyright
© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Clin Cancer Res. 2016 Sep 15;22(18):4585-93
pubmed: 27225694
Lung Cancer. 2017 Mar;105:17-22
pubmed: 28236980
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Invest New Drugs. 2017 Feb;35(1):105-107
pubmed: 27599705
Lung Cancer. 2019 Jan;127:37-43
pubmed: 30642549
Oncotarget. 2017 Feb 25;8(32):53675-53683
pubmed: 28881841
Lung Cancer. 2013 Oct;82(1):109-14
pubmed: 23910906
Lung Cancer. 2018 Apr;118:36-40
pubmed: 29572000
J Thorac Oncol. 2018 Aug;13(8):1138-1145
pubmed: 29874546